Metabolic Effects of Antidepressant Treatment
Open accessAbstract
INTRODUCTION: This study aimed to investigate body measurements, glucose-insulin metabolism, and lipid profile in patients with anxiety and depressive symptoms and also the effects of antidepressant drugs on these metabolic parameters. METHODS: The study included 40 outpatients and 32 healthy controls. The patients received antidepressant treatment (sertraline, escitalopram, fluoxetine, and venlafaxine) for 8 weeks. Body measurements were performed, and lipid, fasting blood glucose, and insulin levels were measured before and after treatment in patients and once in healthy controls. Insulin resistance was evaluated using the homeostasis model assessment (HOMA) index. RESULTS: Body mass index was higher in patients than in healthy controls, and there was no change in patients after treatment. In patients, high-density lipoprotein (HDL) cholesterol levels increased owing to the antidepressant treatment. Insulin level and HOMA index had a tendency to decrease with the treatment in patients and were similar to those of healthy controls before the treatment; however, they became lower than those of healthy controls after the treatment. There was an increase in waist circumference and total and HDL cholesterol levels, whereas there was a decrease in fasting blood glucose levels with treatment in patients using escitalopram. There was no change in body measurements and biochemical and hormone values in patients using fluoxetine, sertraline, and venlafaxine. There was an increase in weight, body mass index, and waist circumference after treatment in patients with depression; however, there was no change in patients with anxiety. CONCLUSION: In patients with psychiatric disorders having anxiety and depressive symptoms, metabolic changes independent of drugs and the metabolic effects of drugs are present.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Many studies have shown that selective serotonin reuptake inhibitors have a negative effect on fat metabolism, contrary to the previously assumed absence of such an effect.
“Despite the previously assumed absence of a pronounced negative effect of selective serotonin reuptake inhibitors on fat metabolism, many studies have shown the opposite.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [149]
A number of studies revealed an increase in TC, TGs, and LDL in the blood of depressed patients following treatment with selective serotonin reuptake inhibitors.
“Thus, a number of studies revealed an increase in the level of TC, concentration of TGs, and LDL in the blood of depressed patients following treatment with selective serotonin reuptake inhibitors [143,147,148,149].”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [149]
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,769 · see citing works
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220 · see citing works
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070 · see citing works
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Serotonin Function and the Mechanism of Antidepressant Action
Delgado, P. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810170011002 · Cited by 930 · see citing works
Major depressive disorder and hypothalamic-pituitary-adrenal axis activity
Vreeburg, S. A., Hoogendijk, W. J. G., van Pelt, J., DeRijk, R. H., Verhagen, J. C. M., van Dyck, R., Smit, J. H., Zitman, F. G., & Penninx, B. W. J. H. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.50 · Cited by 792 · see citing works
Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment
Musselman, D. L., Betan, E. J., Larsen, H., & Phillips, L. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00569-9 · Cited by 670 · see citing works
Obesity among those with mental disorders: a National Institute of Mental Health meeting report.
Allison, D., Newcomer, J., Dunn, A., Blumenthal, J., Fabricatore, A., Daumit, G., Cope, M., Riley, W., Vreeland, B., Hibbeln, J., et al. (2009) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.11.020 · Cited by 411 · see citing works
Weight gain and antidepressants.
Fava, M. (2000) · PubMed · Cited by 384 · see citing works
Maes, M. H. J., Smith, R., Christophe, A., Vandoolaeghe, E., Gastel, A. V., Neels, H. M., Demedts, P., Wauters, A., & Meltzer, H. Y. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09622.x · Cited by 356 · see citing works
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 346 · see citing works
Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia
Thakore, J. H., Mann, J. N., Vlahos, I., Martin, A. J., & Reznek, R. H. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801840 · Cited by 332 · see citing works
Metabolic side effects of antipsychotic medication
Tschoner, A., Engl, J., Laimer, M. W., Kaser, S., Rettenbacher, M. A., Fleischhacker, W. W., Patsch, J. R., & Ebenbichler, C. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01416.x · Cited by 253 · see citing works
Depression: An Important Comorbidity With Metabolic Syndrome in a General Population
Dunbar, J. A., Reddy, P., Davis-Lameloise, N., Philpot, B., Laatikainen, T., Kilkkinen, A., Bunker, S. J., Best, J. D., Vartiainen, E., Kai Lo, S., et al. (2008) · Diabetes Care · doi:10.2337/dc08-0175 · Cited by 241 · see citing works
Depressive Symptoms and the Risk of Type 2 Diabetes
Golden, S. H., Williams, J. E., Ford, D. E., Yeh, H., Sanford, C. P., Nieto, F. J., & Brancati, F. L. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.429 · Cited by 233 · see citing works
Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes
Mika Kivimaki, B., Hamer, M., Batty, G. D., Geddes, J. R., Tabák, Á. G., Pentti, J., Virtanen, M., & Vahtera, J. (2010) · Diabetes Care · doi:10.2337/dc10-1187 · Cited by 196 · see citing works
Obesity, Dyslipidemia, and Diabetes With Selective Serotonin Reuptake Inhibitors
Raeder, M. B., Bjelland, I., Vollset, S. E., & Steen, V. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1219 · Cited by 170 · see citing works
Depression and weight gain: the serotonin connection
Wurtman, J. J. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90032-f · Cited by 149 · see citing works
Sussman, N., Ginsberg, D. L., & Bikoff, J. (2001) · PubMed · Cited by 138 · see citing works
Treatment response and cognitive impairment in major depression: Association with C-reactive protein
Chang, H. H., Lee, I. H., Gean, P. W., Lee, S.-Y., Chi, M. H., Yang, Y. K., Lu, R.-B., & Chen, P. S. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.07.239 · Cited by 120 · see citing works
Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care
Lambert, T. J. R., & Newcomer, J. W. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02374.x · Cited by 115 · see citing works
Lawlor, D. A., Smith, G. D., & Ebrahim, S. B. J. (2003) · BMJ · doi:10.1136/bmj.327.7428.1383 · Cited by 112 · see citing works
Effects of Nefazodone on Body Weight
Sussman, N., Ginsberg, D. L., & Bikoff, J. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0407 · Cited by 108 · see citing works
Ramasubbu, R. (2002) · Medical Hypotheses · doi:10.1016/s0306-9877(02)00244-x · Cited by 104 · see citing works
Medical co‐morbidity risk factors and barriers to care for people with schizophrenia
Muir‐Cochrane, E. (2006) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2006.01002.x · Cited by 104 · see citing works
Lehto, S. M., Hintikka, J. J., NISKANEN, L. K., Tolmunen, T., Koivumaa-Honkanen, H. T., Honkalampi, K. M., & Viinamäki, H. T. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.021 · Cited by 95 · see citing works
Deisenhammer, E. A., Kramer-Reinstadler, K., Liensberger, D., Kemmler, G., Hinterhuber, H., & Wolfgang Fleischhacker, W. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2003.09.007 · Cited by 92 · see citing works
Type of antidepressant therapy and risk of type 2 diabetes in people with depression
Brown, L. C., Majumdar, S. R., & Johnson, J. A. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.07.009 · Cited by 92 · see citing works
Stress Augments Insulin Resistance and Prothrombotic State
Uchida, Y., Takeshita, K., Yamamoto, K., Kikuchi, R., Nakayama, T., Nomura, M., Cheng, X. W., Egashira, K., Matsushita, T., Nakamura, H., et al. (2012) · Diabetes · doi:10.2337/db11-0828 · Cited by 90 · see citing works
Beyazyüz, M., Albayrak, Y., Eğilmez, O. B., Albayrak, N., & Beyazyüz, E. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.2.148 · Cited by 83 · see citing works
Weber-Hamann, B., Gilles, M., Lederbogen, F., Heuser, I., & Deuschle, M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1204 · Cited by 75 · see citing works
Weight Gain Associated With Psychotropic Drugs
Brady, K. T. (1989) · Southern Medical Journal · doi:10.1097/00007611-198905000-00017 · Cited by 63 · see citing works
Lawlor, D. A., Ben‐Shlomo, Y., Ebrahim, S. B. J., Smith, G. D., Stansfeld, S. A., YARNELL, J. W. G., & Gallacher, J. (2005) · BMJ · doi:10.1136/bmj.38377.616921.f7 · Cited by 58 · see citing works
The Effects of Antidepressants on Neuropeptide Y in Patients with Depression and Anxiety
Özsoy, S., Eker, Ö. O., & Abdülrezzak, Ü. (2016) · Pharmacopsychiatry · doi:10.1055/s-0035-1565241 · Cited by 50 · see citing works
Buhl, E. S., Jensen, T. K., Jessen, N., Elfving, B., Buhl, C. S., Kristiansen, S. B., Pold, R., Solskov, L., Schmitz, O., Wegener, G., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00606.2009 · Cited by 43 · see citing works
Monoamine Oxidase Inhibitors and Weight Gain
Cantú, T. G., & Korek, J. S. (1988) · Annals of Pharmacotherapy · doi:10.1177/106002808802201002 · Cited by 42 · see citing works
Further evidence for low serum cholesterol and suicidal behaviour
Sarchiapone, M., Roy, A., Camardese, G., & Risio, S. D. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00198-6 · Cited by 38 · see citing works
Ma, Y., Balasubramanian, R., Pagoto, S., Schneider, K. L., Culver, A. L., Olendzki, B. C., Tinker, L. F., Liu, S., Safford, M. M., Sepavich, D. M., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1223 · Cited by 37 · see citing works
Ma, Y., Balasubramanian, R., Pagoto, S., Schneider, K. L., Hébert, J. R., Phillips, L. S., Goveas, J. S., Culver, A. L., Olendzki, B. C., Beck, J., et al. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301394 · Cited by 31 · see citing works
Changes in Plasma Cholesterol in Mood Disorder Patients: Does Treatment Make a Difference?
Gabriel, A. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.015 · Cited by 26 · see citing works
Depression and Diabetes: More on What the Relationship Might Be
Lyketsos, C. G. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020243 · Cited by 25 · see citing works
Chang, H. H., Chi, M. H., Lee, I. H., Tsai, H. C., Gean, P. W., Yang, Y. K., Lu, R., & Chen, P. S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.008 · Cited by 25 · see citing works
Prediabetes and the risk of diabetes
DEEDWANIA, P. C., & Ahmed, A. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61705-x · Cited by 8 · see citing works
Our experience with antidepressant treatment in the obese and type 2 diabetics.
Svacina, S. (2005) · PubMed · Cited by 6 · see citing works
Correlation of Selective Serotonin Re-Uptake Inhibitor Use with Weight Gain and Metabolic Parameters
Yosmaoglu, A., Fistikci, N., Keyvan, A., Hacioglu, M., Erten, E., Saatcioglu, O., & Kora, K. (2013) · Anatolian Journal of Psychiatry · doi:10.5455/apd.36693 · Cited by 5 · see citing works
Prediabetes and the risk of diabetes
McMurray, J. J. V., Haffner, S. M., Califf, R. M., & Holman, R. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61706-1 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Pan, S.-J., Tan, Y.-L., Yao, S.-W., Xin, Y., Yang, X., Liu, J., & Xiong, J. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.207 · Cited by 63 · see citing works
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works
Homorogan, C., Nitusca, D., Enatescu, V., Schubart, P., Moraru, C., Socaciu, C., & Marian, C. (2021) · Metabolites · doi:10.3390/metabo11070466 · Cited by 19 · see citing works
- Authors
- Olguner Eker, O., Ozsoy, S., Eker, B., & Dogan, H.
- Affiliations
- Kayseri Eğitim ve Araştırma Hastanesi (TR)
- Venue
- Nöro Psikiyatri Arşivi
- Publisher
- Turk Noropsikiyatri Dernegi
- Published
- 2017-05-08
- Volume
- 54
- Issue
- 1
- Pages
- 49-56
- ISSN
- 1300-0667 (ISSN-L)
- 1309-4866
- PMC
- PMC5439472
- OpenAlex
- W2612869838
- Cited by
- 44
- References
- 47
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 6 · 2023: 6 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 2 · 2018: 7 · 2017: 1 · 2016: 1
- FWCI
- 2.97
- Type
- journal article
- Language
- tr
- Open access
- green
- europepmc.org
- Locations
- Nöro Psikiyatri Arşivi (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- antidepressants, metabolic effects, depression, anxiety, body mass index, waist circumference, lipid profile, HDL cholesterol, insulin resistance, fasting blood glucose, sertraline, escitalopram, fluoxetine, venlafaxine, HOMA index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
